LY3410738 is currently being evaluated in a phase I clinical trial in patients with IDH1 mutated solid tumors (NCT04521686) with plans to expand to a phase II trial for patients with CCA that compares LY3410738 combined with gemcitabine and cisplatin in treatment naïve patients to its use as a monotherapy in previously treated patients (74). The gene discussed is IDH1; the disease is cholangiocarcinoma.